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ABSTRACT 
The structural requirements for decreasing cholesterol and triglyceride levels remain largely uninvestigated. Thus a 
systematic investigation of certain N-substituted dibenz[c,e]azepines is necessary. Nine compounds of N-substituted 
derivatives of Dibenz[c,e]azepine-5,7-Dione were synthesized and they were tested for antihyperlipidemic  activity. 
Compounds synthesized (C-1, C-3, C-4 and C-5) significantly lowered the serum total cholesterol, triglyceride and 
LDL (low density lipoprotein) levels and also improved the HDL (high density lipoprotein) level in Triton-WR 1339 
induced hyperlipidemic rats. 
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INTRODUCTION 
Cardio vascular diseases are leading cause of death in 
both industrialized and developing nations. It also 
significantly contributes to the mortality and morbidity 
of human in the industrialized nations 
1,2
. 
Hyperlipidemia is one of the important risk factors 
involved in the development of cardiovascular disease. 
Hyperlipidemia is defined as an elevation of lipids in 
plasma 
3
. Several studies have showed that an intimate 
correlation exists between coronary heart diseases and 
hyperlipidemia, consequently a rational approach to the 
treatment and prevention of coronary heart diseases 
could be by decreasing any elevated levels of lipids in 
plasma 
4,5 
. Although there are many studies have been 
conducted to evaluate the potential hypolipidemic 
effects of synthetic and naturally occurring compounds, 
it is still imperative to find more effective and nontoxic 
drugs. 
In searching for a new class of antihyperlipidemic 
agents, dibenz[c,e] azepines-5,7-dione derivatives have 
been found to possess antihyperlipidemic action via 
lowering the triglycerides and cholesterol levels. The 
detailed study of cyclic imides showed that seven-
member cyclic imides such as dibenz[c,e]azepines-5,7-
diones could possess the antihyperlipidemic activity 
6
. In 
the present study, we aimed to synthesize a new series of 
dibenz(c,e)azepines-5,7-diones derivatives and to 
investigate their hypolipidemic activity using Triton 
WR-1339 induced hyperlipidemic rats as a model. 
MATERIAL AND METHODS  
Chemicals and instruments 
All chemicals and solvents used were of analytical grade 
and purchased. The melting points were determined in 
open capillaries and are uncorrected. Purity of the 
compounds was checked by thin layer chromatography 
(TLC). TLC was performed on precoated (0.25 mm) 
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silica gel GF plates (E. Merck, Germany). The infra red 
spectra were recorded by using ATR-IR model ALPHA 
Bruker, Germany. 1H NMR spectra were recorded on a 
BrukerAvance II 400 MHz NMR spectrometer; 
Chemical shifts are expressed in ppm with reference to 
TMS.  
Animals 
Healthy Wistar male rats weighing 210-230 g were used. 
The animals had free access to a standard commercial 
diet and water ad libitum and were kept in rooms 
maintained at 25 °C with a 12-h light/dark cycle. The 
animals were used after an acclimatization period of 7 
days to the laboratory environment. The experiments 
were performed during the light portion (0800–1600 h). 
The experimental protocol and procedures used in this 
study were approved by IAEC of Lachoo Memorial 
College of Science and Technology, Pharmacy Wing, 
Jodhpur.  
Synthesis and scheme 
The scheme of synthesis of test compounds is presented 
in Figure 1-2. Diphenic anhydride was prepared from 
reported procedure. A mixture of diphenic anhydride 
(11.21 gm, 0.05 mole) and appropriate aromatic and 
hetro-aromatic amine (0.05 mole) in Xylene (150 ml) 
was heated under reflux for 4-5 hours with stirring. The 
mixture was cooled and the resulting solid product (a 
diphenic acid derivative) was filtered, dried and 
transferred to 250 ml RBF containing acetic anhydride 
(150 ml) and anhydrous sodium acetate (10 gm) 
equipped with reflux condenser. The mixture was heated 
for 3-4 hours and transferred to 500 ml ice cooled water. 
The precipitate was washed with water and crystallized 
with ethanol 
7, 8
 
The compounds were characterized by qualitative 
elemental analysis, melting point and spectroscopic 
analysis 
9
. Melting point ranges of newly synthesized 
compounds were determined by open glass tube using 
visual melting apparatus and are uncorrected. The 
temperature at which compound started melting to the 
temperature at which it completely melted was taken as 
the melting point range. All the new derivatives were 
subjected to elemental detection for elements like 
Chlorine, Nitrogen and Sulphur. Qualitative assessment 
for the presence of these atoms was done by preparing 
Lassaign extract of the compounds. IR spectrum of 
compounds was recorded on an ATR 
Spectrophotometer.  
1
H-NMR spectrum of newly 
synthesised compounds was recorded on NMR 
spectrometer at 400MHz in chloroform and Dimethyl 
sulfoxide (DMSO) using Tetramethylsilane (TMS) as 
internal standard. Chemical shift, delta δ in ppm was 
recorded. 
Triton WR 1339 induced anti-hyperlipidemic activity 
Seventy two rats were arranged in 12 groups (6 animals 
each) and were deprived of food but were allowed free 
access to drinking water. Group I treated with vehicle 
(distilled water) served as normal group, in all other 
groups (II to XII) hyperlipidemia was induced by a 
single intraperitoneal (ip) injection of triton WR 1339 
(300 mg/kg body wt) dissolved in normal saline (pH 7.4)
 
10
. Group II was kept as control, without any further 
treatment. Group III was treated with atorvastatin 10 
mg/kg body wt. Group IV to XII were treated with 
Dibenz [c,e] Azepine-5,7-Dione derivatives compound I 
to IX in dose of 150 mg/kg. The compounds and 
atorvastatin were administered by oral gavage one hour 
before the triton administration. Animals were sacrificed 
24 h after the administration. Blood was collected from 
tail vein of each animal and the serum was separated and 
used for the estimation of serum lipid profile.  
Statistical Analysis 
Results were expressed as mean values and standard 
deviations. The data were analyzed by one way ANOVA 
followed by and Dunnett’s test with triton control group 
using Prism 3.0. P value less than 0.05 were considered 
significant. 
RESULT 
Synthesis and characterization of Dibenz[c,e]azepine-
5,7-Dione derivatives  
Nine derivatives of Dibenz[c,e]azepine-5,7-dione or 
Diphenimide (C-1 to C-9) were synthesized from 
Diphenic anhydride or Dibenz[c,e]oxepine-5,7-Dione. 
Diphenic anhydride was synthesized from anthrinillic 
acid. Characterization of the synthesized compounds 
were carried out on the basis of chemical data and 
spectral data.   
 
  
Table 1: Melting point, percentage yield, molecular formula and molecular weight of Dibenz [c, e] azepine-5,7-Dione 
derivatives. 
Compound 
No. 
Molecular 
formula 
Melting point 
Range (
0
C) 
% Yield Molecular weight 
(Da) 
Log P value 
(calculated) 
C-1 C20H13NO2 203-05 76.84 299.32 3.79±0.62 
C-2 C22H15NO3 242-48 73.82 341.36 3.55±0.63 
C-3 C21H15NO2 147-49 68.29 313.35 4.25±0.62 
C-4 C20H13NO3 250-52 71.04 315.32 2.96±0.62 
C-5 C20H14N2O2 192-94 62.35 314.34 2.21±0.63 
C-6 C20H12N2O4 260-62 74.35 344.32 4.07±0.63 
C-7 C20H12ClNO2 219-21 67.71 333.77 4.632±0.63 
C-8 C19H12N2O2 238-40 65.93 300.31 2.80±0.63 
C-9 C20H14N2O2 226-28 65.53 314.34 3.26±0.63 
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Melting point, percentage yield, molecular formula, 
molecular weight and log p of synthesised compounds 
are shown in Table 1. The Spectroscopic data (IR and 
1
H-NMR) of synthesised compounds are illustrated 
in Table 2. 
 
Table 2: Spectroscopic data of Dibenz[c,e]azepine-5,7-Dione derivatives 
 
 
 
 
 
 
Comp. Structure Characterisitc IR (KBr) Cm
-1
 NMR Chemical Shift  δ (ppm) 
 C -1 
N
O
O
 
1600-1400 Str. (C=C of aryl) 
1655 Str. (C=O Imide),  
3150-3000 (Str. Ar C=C-H Str.) 
6.51  - 7.44 (m, 5H, N-Ar-H)  
7.76  -8.21 (m, 8H,  Ar-H)  
 
  C-2 
N
O
O
COCH3
 
1690 Str. (Ar C=O  )   2.54 (s,  3H, COCH3) 
 7.78 -7.80 (m, 4H, N-Ar-H)  
 
  C-3 
N
O
O
CH3
 
2925 Str. (C-H of Ar CH3) 
3030 Str.(Ar =C-H) 
2.29  (s,  3H, CH3) 
7.22 - 7.65 (m, 4H, N-Ar-H)  
 
 C -4 
N
O
O
OH
 
3315 Str. (Phenolic OH) 7.04 - 7.38 (m, 4H, N-Ar-H)  
9.17  (s, 1 H, Ar- OH) 
 
 C -5 
N
O
O
NH2
 
3445 Str. (Ar NH2)  
3360 Str. (Ar NH2)  
Due to symmetrical and 
asymmetrical stretching 
5.85  (s, 2H, Ar-NH2) 
6.96 - 6.99  (m, 4H, N-Ar-H)  
 
 C -6 
N
O
O
NO2
 
1360 Str. (N-O of NO2) 
1521 Str. (N-O of NO2) 
 
7.72-8.49  (m, 4H, N-Ar-H)  
 
  C-7 
N
O
O
Cl
 
842 Str. C-Cl (Ar-Cl) 
1590 Str ( C=C of Ar) 
3084 Str. (Ar C-H of C6H4Cl) 
7.37-7.61  (m, 4H, N-Ar-H)  
 
  C-8 
N
O
O
N
 
1670 Str. (C=N of pryridine) 
2948-3176  Str. (=CH of Pyridine) 
 
7.75-8.68 (m, 4H, Pyridine-H) 
  C-9 
N
O
O
N
CH3
 
1662 Str. (C=N of pyridine) 
2954-3068  Str. (=CH of Pyridine) 
2850-2750 Str, ( CH3 of Pyrindine) 
2.70 (s, 3H, CH3 with pyridine) 
7.51-8.42 (m, 4H, Pyridine H) 
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Table 3: Effect of different derivatives of Dibenz[c,e]azepine-5,7-Dione on serum lipid levels in Triton WR-1339 
(TRI) induced hyperlipidemic rats. 
Groups Treatment dose 
(mg/kg) 
Total Cholesterol 
(mg/dl) 
Triglyceride 
(mg/dl) 
HDL-C 
(mg/dl) 
LDL-C 
(mg/dl) 
Normal Vehicle 82.83±4.64 96.08±4.37 36.17±2.95 29.83±2.37 
Triton control 300 388.17±6.37 529.08±7.71 24.33±1.43 145.33±5.85 
Triton +Atorvastatin 10 151.17±6.48 375.17±5.49 33.42±1.21 45.17±2.52 
Triton + C-1 150 294.33±18.96* 479.50±15.44* 29.33±1.41* 110.17±8.04* 
Triton + C-2 150 380.67±9.26 524.42±8.60 25.17±1.11 133.17±3.72 
Triton + C-3 150 281.17±7.32* 433.04±20.93* 30.67±0.92* 87.33±5.27* 
Triton + C-4 150 262.33±7.20* 376.08±10.92* 32.17±1.19* 65.50±1.06* 
Triton + C-5 150 274.17±8.42* 426.33±19.45* 31.33±1.05* 69.33±1.99* 
Triton + C-6 150 391.50±7.36 517.33±7.41 24.67±1.52 138.83±4.92 
Triton + C-7 150 368.83±6.05 519.83±6.61 25.83±1.17 139.67±5.41 
Triton + C-8 150 386.17±6.70 516.50±13.37 25.17±1.56 135.33±11.56 
Triton + C-9 150 372.33±13.94 501.50±10.92 26.17±1.01 140.33±8.24 
Values reported as Mean ± SEM (n=6). The data were analyzed by one way ANOVA followed by and Dunnett test. *P<0.05 as compared 
with triton control group. 
Antihyperlipidemic Activity 
Induction of Hyperlipidemia by Triton WR-1339 
The levels of plasma total cholesterol (TC), triglyceride 
(TG), high-density lipoprotein (HDL) and low-density 
lipoprotein (LDL) levels of all groups treated for 24 h 
after Triton administration are shown in Table 3. In 
comparison with the normal group, Triton WR-1339 
caused a significant increase in TC, TG and LDL 
measured 24 h after Triton injection. Triton WR-1339 
caused a significant decrease in HDL cholesterol levels 
in the hyperlipidemic control (HG), at 24 h after Triton 
administration, in comparison with the normal group 
(Figure 3-6 and Table 3).  
Effect of synthesized compounds (C-1 to C-9) on 
plasma level of Total Cholesterol (TC), Triglyceride 
(TG) and Low Density Lipoprotein (LDL) 
The oral administration of Dibenz[c,e]azepine-5,7-Dione 
derivatives compound 1,3, 4 and 5 to rats significantly 
(P<0.05) decreased the plasma level of TC, TG and LDL  
in comparison to the triton control group (Figure 3,4,5  
and Table 3). 
Effect on plasma level of HDL 
The plasma level of HDL-C significantly increased 
(P<0.05) in rats treated with compound 1,3, 4 and 5 in 
comparison to the triton control group (Figure 4 and 
Table 3). 
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Figure 1: Scheme for synthesis of Dibenz[c,e]azepine-5,7-Dione derivatives compounds one and two 
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Figure 2: Scheme for synthesis of Dibenz[c,e]azepine-5,7-Dione derivatives compounds  three to nine. 
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Figure 3: Effect of different derivatives of Dibenz[c,e]azepine-5,7-Dione on total cholesterol in Triton WR-1339 (TRI) 
induced hyperlipidemic rats. (NC: Normal control, TC: Triton control, Ator: Atorvastatin, C-1,2,3,4,5,6,7,9 : Test 
compound 1,2,3,4,5,6,7,9), *P<0.05 as compared with triton control group. 
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Figure 4: Effect of different derivatives of Dibenz[c,e]azepine-5,7-Dione on HDL level in Triton WR-1339 (TRI) 
induced hyperlipidemic rats. (NC: Normal control, TC: Triton control, Ator: Atorvastatin, C-1,2,3,4,5,6,7,9 : Test 
compound 1,2,3,4,5,6,7,9), *P<0.05 as compared with triton control group. 
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Figure 5: Effect of different derivatives of Dibenz[c,e]azepine-5,7-Dione on triglyceride level  in Triton WR-1339 
(TRI) induced hyperlipidemic rats. (NC: Normal control, TC: Triton control, Ator: Atorvastatin, C-1,2,3,4,5,6,7,9 : 
Test compound 1,2,3,4,5,6,7,9), *P<0.05 as compared with triton control group. 
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Figure 6: Effect of different derivatives of Dibenz[c,e]azepine-5,7-Dione on LDL level in Triton WR-1339 (TRI) 
induced hyperlipidemic rats. (NC: Normal control, TC: Triton control, Ator: Atorvastatin, C-1,2,3,4,5,6,7,9 : Test 
compound 1,2,3,4,5,6,7,9), *P<0.05 as compared with triton control group. 
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DISCUSSION 
Triton WR-1339 acts as a surfactant and suppresses the 
action of lipases to block the uptake of lipoproteins from 
circulation by extra hepatic tissues, resulting into 
increased blood lipid concentration [Kumar]. The 
biphasic nature of triton-induced hyperlipidemia is 
helpful in understanding the mode of action of 
hypolipidemia agents. Drugs interfering with lipid 
biosynthesis or uptake will be active in the synthesis 
phase. 
In searching for a new class of antihyperlipidemic 
agents, many compounds having open imide or cyclic 
imide function have been found to possess 
antihyperlipidemic action via lowering the triglycerides 
and cholesterol levels. Some Dibenz[c,e]azepine-5,7-
Dione compound are more superior in many cases than 
clofibrate.  
In this study, cholesterol, triglyceride and LDL levels 
were found to be elevated 24 h after the triton WR-1339 
administration which was effectively decreased by 
treatment with oral administration of 
Dibenz[c,e]azepine-5,7-Dione compounds 1,3, 4 and 5.  
The reduction of plasma cholesterol and triglyceride in 
test compound treated rats was associated with a 
decrease in LDL (Patel et al., 2003). These findings 
suggest that the cholesterol-lowering activity of test 
compound probably mediated through HMG-CoA 
reductase activity or lipoprotein lipase activity, 
responsible to decrease plasma triglycerides levels 
11
. 
However, more studies are needed to identify the exact 
mechanisms of the compound 1, 3, 4 and 5. 
CONCLUSION 
In conclusion, it may be stated that the results of the 
present study demonstrated new properties of 
synthesized derivatives of dibenz[c,e]azepines-5,7-
diones as potent lipid lowering agents and these 
beneficial activities may contribute to their 
cardioprotective and antiatherosclerotic role. 
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